2019
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For ImmunoTherapy Of Cancer 2019, 7: 172. PMID: 31291990, PMCID: PMC6617639, DOI: 10.1186/s40425-019-0643-8.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsEGFR-mutant lung cancerMutant lung cancerTumor regressionErlotinib treatmentLung cancerImmune cellsLung tumorsMouse modelEffects of TKIsGrowth factor receptor tyrosine kinase inhibitorsTumor-infiltrating immune cellsDrug resistanceReceptor tyrosine kinase inhibitorsInflammatory immune cellsInflammatory T cellsEffect of erlotinibEGFR mutant lung tumorsInflammatory cellsImmunological profileT cellsCD40 agonistsImmunostimulatory effectsAlveolar macrophagesErlotinib
2017
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
Cecchini M, Sklar J, Lacy J. EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance. Journal Of The National Comprehensive Cancer Network 2017, 15: 1085-1089. PMID: 28874593, DOI: 10.6004/jnccn.2017.0151.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTyrosine kinase inhibitorsMetastatic pancreatic ductal adenocarcinomaEGFR Exon 19 DeletionEGFR tyrosine kinase inhibitorsImmune checkpoint inhibitorsMetastatic pancreatic cancerExon 19 deletionsEpidermal growth factor receptorGrowth factor receptorAdvanced diseaseCheckpoint inhibitorsMultidrug chemotherapyPancreatic cancerDisease progressionDuctal adenocarcinomaPancreatic adenocarcinomaActionable mutationsTumor typesKinase inhibitorsExon 19Factor receptorAdenocarcinomaPatientsErlotinibP3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S. P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1302-s1303. DOI: 10.1016/j.jtho.2016.11.1841.Peer-Reviewed Original Research
2016
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw594.005.Peer-Reviewed Original Research441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O’Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27: ix141. DOI: 10.1016/s0923-7534(21)00599-8.Peer-Reviewed Original ResearchPhase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.Peer-Reviewed Original Research
2014
Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer
Gettinger S, Chow L, Borghaei H, Shen Y, Harbison C, Chen A, Rizvi N. Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s34-s35. DOI: 10.1016/j.ijrobp.2014.08.210.Peer-Reviewed Original ResearchSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
Rizvi N, Chow L, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen A, Gettinger S. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. Journal Of Clinical Oncology 2014, 32: 8022-8022. DOI: 10.1200/jco.2014.32.15_suppl.8022.Peer-Reviewed Original ResearchA multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
Neal J, Wakelee H, Feliciano J, Goldberg S, Morgensztern D, Das M, Heist R, Lennes I, Muzikansky A, Edelman M, Gettinger S, Sequist L. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8088-8088. DOI: 10.1200/jco.2014.32.15_suppl.8088.Peer-Reviewed Original ResearchReduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J. Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery 2014, 4: 606-619. PMID: 24535670, PMCID: PMC4011693, DOI: 10.1158/2159-8290.cd-13-0741.Peer-Reviewed Original ResearchConceptsLung cancerMAP-ERK kinase (MEK) inhibitorsEGF receptorEGFR-mutant lung adenocarcinomaKinase inhibitorsHuman lung cancer cell linesResistance of lungSubgroup of patientsLung cancer cell linesCancer cell linesClinical responsivenessCombination therapyEGFR-TKIEGFR mutationsErlotinib resistanceLung adenocarcinomaRAS-ERK signalingEGFR inhibitionMEK inhibitorsErlotinibReduced expressionNF1 expressionPatientsCell linesNeurofibromin levels
2012
Occupy EGFR
Park JH, Lemmon MA. Occupy EGFR. Cancer Discovery 2012, 2: 398-400. PMID: 22588876, PMCID: PMC3354646, DOI: 10.1158/2159-8290.cd-12-0144.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor (EGFR) mutationsNon-small cell lung cancer (NSCLC) tumorsCell lung cancer tumorsDifferent EGFR mutationsTreatment of glioblastomaLung cancer tumorsDistinct receptor conformationsEGFR mutationsReceptor mutationsEGFR inhibitorsCancer tumorsInhibitor efficacyEGFR mutantsEGFR variantsEGFRGlioblastomaDrug selectivityReceptor conformationNew studiesBarkovichErlotinibGefitinibTumors
2011
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
Komaki R, Blumenschein G, Wistuba I, Lee J, Allen P, Wei X, Welsh J, O'Reilly M, Herbst R, Tang X, Meyn R, Liu D, Hong W. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. Journal Of Clinical Oncology 2011, 29: 7020-7020. DOI: 10.1200/jco.2011.29.15_suppl.7020.Peer-Reviewed Original ResearchPhase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
Stinchcombe T, Socinski M, Moore D, Gettinger S, Decker R, Petty W, Blackstock A, Schwartz G, Lankford S, Morris D. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 7016-7016. DOI: 10.1200/jco.2011.29.15_suppl.7016.Peer-Reviewed Original ResearchThe role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin.
Maitah M, Ali S, LoRusso P, Sarkar F, Gadgeel S. The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. Journal Of Clinical Oncology 2011, 29: 10537-10537. DOI: 10.1200/jco.2011.29.15_suppl.10537.Peer-Reviewed Original Research
2010
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
Ilson D, Kelsen D, Shah M, Schwartz G, Levine D, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2010, 117: 1409-1414. PMID: 21425140, PMCID: PMC3116987, DOI: 10.1002/cncr.25602.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorTyrosine kinase inhibitorsEGFR-negative tumorsCell carcinomaEsophageal cancerOral EGFR tyrosine kinase inhibitorEpidermal growth factor receptor statusEGFR tyrosine kinase inhibitorsPhase 2 trialTreating esophageal cancerGrowth factor receptorPartial responseSquamous cellsSkin rashGastroesophageal junctionSolid tumorsMetastatic cancerTumor progressionFactor receptorKinase inhibitorsErlotinibCarcinomaTumorPatientsA phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
Wakelee H, Gettinger S, Engelman J, Janne P, West H, Subramaniam D, Leach J, Wax M, Yaron Y, Lara P. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2010, 28: 3017-3017. DOI: 10.1200/jco.2010.28.15_suppl.3017.Peer-Reviewed Original ResearchA phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
Moldovan C, Soria J, LoRusso P, Guthrie T, Song C, Nguyen L, Martini J, Infante J, Burris H. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2010, 28: 3070-3070. DOI: 10.1200/jco.2010.28.15_suppl.3070.Peer-Reviewed Original ResearchBATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)
Hong W, Herbst R, Kim E. BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination). 2010 DOI: 10.21236/ada542458.Peer-Reviewed Original Research
2009
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungDisease ProgressionDisease-Free SurvivalErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm Recurrence, LocalPrecision MedicinePredictive Value of TestsProteomeQuinazolinesConceptsNon-small cell lung cancer patientsCell lung cancer patientsAdvanced NSCLC patientsCombination of erlotinibLung cancer patientsToxic regimenNSCLC patientsPretreatment serumCancer patientsWorse outcomesProteomic classifierBlinded mannerPatientsErlotinibBevacizumabVeriStratSurvivalTreatmentRegimenProgressionSerumInitial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer
Rusthoven K, Feigenberg S, Raben D, Kane M, Song J, Nicolaou N, Mehra R, Burtness B, Swing R, Chen C. Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s408. DOI: 10.1016/j.ijrobp.2009.07.935.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply